• Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate
• SIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy data
• Program...

  or login to read the full story

  Email this article to a friend

  or share it with one of these popular networks:

  • DIGG
  • FACEBOOK
  • STUMBLEUPON
  • MIXX
  • YAHOO BUZZ
  • DELICIOUS
  • REDDIT
  • NEWSVINE